臨床検査一覧
米国のCLIA/CAP認定施設にて実施している主要な臨床検査約300種類の一覧です。お探しの検査の記載がない場合は、ご連絡ください。
| 検査名 | 検体 | 技術 | 疾患 | 用途 |
| 17-OH Progesterone | Blood | LC-MS/MS | Congenital adrenal hyperplasia | Diagnosis, treatment selection |
| Adipophilin | FFPE tissue | IHC | Cutaneous lesions | Diagnosis |
| AFB (Acid Fast Bacteria) | Body fluids | Culture/dye staining | Tuberculosis | Diagnosis |
| ALK D5F3 | FFPE tissue | IHC | NSCLC, inflammatory myofibroblastic tumor | Treatment selection |
| ALK1 | FFPE tissue | IHC | NSCLC, inflammatory myofibroblastic tumor | Diagnosis |
| Alpha-1 Antitrypsin (A1AT) | Serum | Immunoassay | COPD | Diagnosis |
| Amyloid (Congo Red) | FFPE tissue | IHC | Amyloidosis | Diagnosis |
| Androgen Receptor (AR) | FFPE tissue | IHC | Prostate cancer | Treatment selection |
| Angiotensin-Converting Enzyme (ACE) | Serum | Enzymatic | Sarcoidosis, others | Diagnosis |
| APOE Genotype | Blood | PCR | Alzheimer’s Disease, Type III hyperlipoproteinemia | Prognosis |
| Apolipoprotein A1 (ApoA1) | Serum | Immunoassay | Cardiovascular disease | Prognosis |
| Apolipoprotein B (ApoB) | Serum | Immunoassay | Cardiovascular disease | Prognosis |
| Aquaporin 4 | Serum | Cell culture/FACS | Neuromyelitis optica, autoimmune AQP4 channelopathy | Diagnosis |
| Arginase-1 | FFPE tissue | IHC | Hepatocellular carcinoma | Diagnosis |
| B Cell Gene Rearrangement / clonality | Body fluids | PCR/GE | Lymphoproliferative diseases | Diagnosis |
| B. parapertussis | Nasopharyngeal aspirate, serum | PCR | Bordetella parapertussis infection | Diagnosis |
| B. pertussis | Serum | PCR | Bordetella pertussis infection | Diagnosis |
| Babesia Species | Blood | PCR | Babesiosis | Diagnosis |
| Basal Cell Cocktail | FFPE tissue | IHC | Benign and malignant prostatic lesions | Diagnosis |
| Bcl1/Cyclin D1 | FFPE tissue | IHC | Lymphoproliferative diseases | Diagnosis |
| Bcl2 | FFPE tissue | IHC | Lymphoma | Diagnosis |
| Bcl6 | FFPE tissue | IHC | Lymphoma | Diagnosis |
| BCR/ABL1 Mutation Analysis | Blood, BM | PCR | Leukemias | Treatment selection |
| Beta Catenin | FFPE tissue | IHC | Pancreatic, liver, lung and some small soft-tissue cancers | Diagnosis |
| BKV (BK Virus) | Plasma | PCR | Nephropathy in renal transplant recipients | Diagnosis / Prognosis |
| BRAF | Tissue | PCR | Melanoma | Treatment selection |
| BRCA 1/2 | Blood | NGS | Breast cancer, ovarian cancer | Prognosis |
| C. albicans | Blood, bodily fluids | ELISA, PCR | Candidiasis | Diagnosis |
| C. difficile | Feces | PCR | Clostridium difficile infection | Diagnosis |
| Calcitonin | Serum | Immunoassay | Medullary thyroid carcinoma | Diagnosis / Monitoring |
| Calponin | FFPE tissue | IHC | Breast carcinoma | Diagnosis |
| Calprotectin | Fecal | ELISA | Inflammatory bowel disease | Diagnosis |
| CALR Exon 9 Mutations | Blood, BM | PCR | Myeloproliferative neoplasm | Diagnosis |
| Calretinin | FFPE tissue | IHC | Mesotheliomas | Diagnosis |
| Cancer Antigen 125 (CA125) | Blood | Immunoassay | Ovarian cancer | Diagnosis / Monitoring |
| Carbohydrate Antigen 19-9 (CA19-9) | Serum | Immunoassay | Pancreatic cancer | Diagnosis / Monitoring |
| CD 1a | FFPE tissue | IHC | Lymphoblastic leukemia/lymphoma of T-cell lineage | Diagnosis |
| CD10 | FFPE tissue | IHC | Leukemias and lymphomas | Diagnosis |
| CD117 (KIT) | FFPE tissue | IHC | Gastrointestinal stromal tumors | Diagnosis |
| CD138 | FFPE tissue | IHC | Plasma cell neoplasms | Diagnosis |
| CD15 | FFPE tissue | IHC | Leukemias and lymphomas | Diagnosis |
| CD163 | FFPE tissue | IHC | Diseases with macrophage/monocyte involvement | Diagnosis |
| CD176 | FFPE tissue | IHC | Various tumors | Diagnosis |
| CD2 | FFPE tissue | IHC | T-cell lymphoma | Diagnosis |
| CD20 | Blood | Flow cytometery | Immunodeficiencies | Diagnosis |
| CD21 | FFPE tissue | IHC | Follicular dendritic cell sarcoma | Diagnosis |
| CD23 | FFPE tissue | IHC | Low-grade B-cell lymphomas | Diagnosis |
| CD3 | Blood | Flow cytometery | T cell neoplasms | Diagnosis |
| CD30 | FFPE tissue | IHC | A variety of CD30+ neoplasms | Prognosis |
| CD31 | FFPE tissue | IHC | Endothelial neoplasms / angiogenesis | Prognosis |
| CD34 | FFPE tissue | IHC | Various tumors | Prognosis |
| CD38 | FFPE tissue | IHC | Lymphoproliferative and plasma cell proliferative disorders | Diagnosis |
| CD4 | Blood | Flow cytometery | Immunodeficiency | Monitoring |
| CD43 | FFPE tissue | IHC | T-cell lymphomas | Diagnosis |
| CD44 | FFPE tissue | IHC | Various tumors | Prognostic |
| CD45 | FFPE tissue | IHC | Leukemia/lymphoma | Diagnosis |
| CD45RO | Blood | Flow cytometery | Immunodeficiency | Monitoring |
| CD5 | FFPE tissue | IHC | B-cell lymphomas | Diagnosis |
| CD56 | FFPE tissue | IHC | Tumors with neuroendocrine differentiation | Diagnosis |
| CD57 | FFPE tissue | IHC | Tumors of neuroectodermal origin | Diagnosis |
| CD63 | Blood | Flow cytometery | Chronic urticaria | Prognosis |
| CD68 (KP1) | FFPE tissue | IHC | Hematolymphoid neoplasms | Diagnosis |
| CD7 | FFPE tissue | IHC | T-cell lymphoma | Diagnosis |
| CD79A | FFPE tissue | IHC | Leukemias and lymphomas | Diagnosis |
| CD8 | Blood | Flow cytometery | Therapeutic immunosuppression | Monitoring |
| CD99 | FFPE tissue | IHC | Ewing sarcoma, neuroectodermal tumors | Diagnosis |
| CDX2 | FFPE tissue | IHC | Carcinomas of intestinal origin | Diagnosis |
| CEA | Serum | Immunoassay | Colorectal cancer and other tumors | Monitoring |
| CEBPA Mutation | Blood, BM | Sequencing | Acute myeloid leukemia (AML) | Diagnosis, prognosis |
| Celiac Genotype | Blood | PCR/Luminex | Celiac disease | Prognosis |
| Cervical DNA-Dtex (3q26, 5p15) | Cervical material | FISH | Cervical cancer | Prognosis |
| CFTR | Blood | NGS | Cystic fibrosis | Treatment selection |
| CH50 (Complement) | Serum | Liposome method | Complement abnormalities | Diagnosis |
| Chlamydia | Various | PCR/Chemiluminescence | Chlamydia trachomatis infection | Diagnosis |
| Chromogranin A (CGAK) | Serum | Immunoassay | Carcinoid tumors, neuroendocrine tumors, prostate cancer | Diagnosis, prognosis, monitoring |
| CK- (OSCAR) | FFPE tissue | IHC | Carcinomas of unknown origin | Diagnosis |
| CK- AE1/AE3 | FFPE tissue | IHC | Poorly differentiated malignant tumors | Diagnosis |
| CK HMW (34betaE12) | FFPE tissue | IHC | Prostate cancer | Diagnosis |
| CK-19 | FFPE tissue | IHC | Carcinomas with ductal or glandular differentiation | Diagnosis |
| CK-20 | FFPE tissue | IHC | Carcinomas of unknown origin | Diagnosis |
| CK-5/6 | FFPE tissue | IHC | Squamous cell carcinoma and adenocarcinoma, atypical proliferations of the breast | Diagnosis |
| CK-7 | FFPE tissue | IHC | Prostate cancer, carcinoma, sarcomas, primary biliary cirrhosis | Diagnosis, prognosis |
| CK-8 | FFPE tissue | IHC | Epithelial cancer, Anaplastic thyroid carcinoma | Diagnosis |
| CK-8 & 18 | FFPE tissue | IHC | Carcinoma, adenocarcinoma | Diagnosis, prognosis |
| CK-AE1/AE3 | FFPE tissue | IHC | Poorly differentiated malignant tumors | Diagnosis |
| CK-CAM 5.2 | FFPE tissue | IHC | Rectal carcinoma, stomach carcinoma, esophageal carcinoma, bile duct carcinoma, metastatic carcinoma, glioblastoma multiforme, uterine tumors, Paget’s disease, pagetoid squamous cell carcinoma | Diagnosis, prognosis, monitoring |
| CMV (Cytomegalovirus) | Body fluids | PCR | Cytomegalovirus infection | Diagnosis |
| CMV (Cytomegalovirus) Antibody | Serum | Immunoassay | Cytomegalovirus infection | Diagnosis |
| Common Acute Lymphocytic Leukemia Antigen (CD 10) | FFPE tissue | IHC | Acute lymphocytic leukemia, Burkitt lymphoma, follicular germinal center lymphoma | Diagnosis |
| Complement 3 (C3) | Serum | Turbidity | Systemic lupus erythematosus and others | Diagnosis / Monitoring |
| Copper Stain | FFPE tissue | Chemical | Wilson’s disease | Diagnosis |
| Covid-19 Antibody | Nasal or throat swab | PCR | Covid-19 infection | Diagnosis |
| Covid-19 Nucleic acid | Nasal or throat swab | Immunoassay | Covid-19 infection | Diagnosis / Monitoring |
| Crystal Violet Amyloid | FFPE tissue | Chemical | Amyloidosis | Diagnosis |
| C-Telopeptide | Serum | Immunoassay | Osteoporosis, Paget’s disease (bone resorption marker), osteopenia | Monitoring |
| Cyclin D1 | FFPE tissue | IHC | Low-grade B-cell lymphomas | Diagnosis |
| CYP2C19 Genotype | Blood, saliva | PCR | Altered metabolism of drugs | Treatment selection |
| CYP2D6 | Blood, saliva | PCR | Altered metabolism of drugs | Treatment selection |
| CYP450 2C9-VKORC1 | Blood, saliva | PCR | Altered metabolism of warfarin (Coumadin), cardiovascular disease | Treatment selection |
| Cystic Fibrosis 139 | Blood, others | PCR/Luminex | Cystic fibrosis | Diagnosis |
| Cystic Fibrosis 39 | Blood, others | PCR/Luminex | Cystic fibrosis | Diagnosis |
| Desmin | FFPE tissue | IHC | Leiomyosarcomas, rhabdomyosarcomas | Diagnosis |
| DHEA | Serum | LC/MS | Hyperandrogenism, congenital adrenal hyperplasia (CAH), premature adrenarche | Diagnosis |
| DHTS (Dihydrotestosterone) | Serum | LC/MS | Prostate disease, benign prostatic hyperplasia | Monitoring |
| DOG-1 | FFPE tissue | IHC | Gastrointestinal stromal tumors (GISTs) | Diagnosis |
| EBV (Epstein-Barr Virus) Antibody | Serum | Immunoassay | Epstein-Barr virus infection | Diagnosis |
| Ecadherin | FFPE tissue | IHC | Breast cancer | Diagnosis |
| EGFR 29 Mutation Panel | FFPE tissue | PCR | Non-small cell lung cancers (NSCLCs) | Treatment selection |
| Elastic Stain | FFPE tissue | Chemical | Elastic tissue disorders, alopecia, inflammatory skin disorders and neoplastic proliferations. | Diagnosis |
| EMA | Serum | Immunoassay | Dermatitis herpetiformis, celiac disease | Diagnosis, monitoring |
| Ep-CAM (BER-Ep4) | FFPE tissue | IHC | Basal cell carcinoma of the skin, squamous cell carcinoma of the skin, pulmonary adenocarcinoma, pulmonary mesothelioma | Diagnosis |
| Epi proColon | Plasma | PCR | Colorectal cancer (CRC) | Diagnosis |
| ER | FFPE tissue | IHC | breast, cervix, endometrium, uterus, ovary, and prostate cancer | Diagnosis, treatment selection |
| ERG | FFPE tissue | IHC | Prostate cancer | Diagnosis |
| Estradiol | Serum | LC-MS/MS | Hypogonadism, oligo-amenorrhea, hypogonadal premenopausia, feminization, gynecomastia, disorders of sex steroid metabolism, adrenal tumors | Diagnosis, monitoring |
| Estrogens Fractionated | Serum | LC-MS/MS | Precocious and delayed puberty, disorders of sex steroid metabolism, hypogonadism, oligo-amenorrhea, menopause, andropause, feminization, gynecomastia, estrogen-producing neoplasms | Diagnosis, prognosis, monitoring, treatment selection |
| Estrone | Serum | LC-MS/MS | Precocious and delayed puberty, disorders of sex steroid metabolism, osteoporosis | Diagnosis, monitoring |
| Factor 13A | FFPE tissue | IHC | Acquired digital fibrokeratomas, angiofibromas, oral fibroma, histiocytomas | Diagnosis |
| Factor V Leiden | Blood | PCR | Thrombophilia | Diagnosis |
| Factor VIII Activity | Plasma | APTT | Hemophilia A, von Willebrand disease, | Diagnosis, monitoring |
| Fibrinogen | Plasma | Immunoprecipitation | Afibrinogenemia, hypofibrinogenemia, dysfibrinogenemias, chronic hepatitis, hepatoma, advanced liver disease, renal diseases, chronic glomerulonephritis, hypernephroma | Diagnosis, monitoring |
| Fragile X | Various | PCR | Fragile X syndrome, fragile X tremor/ataxia syndrome, premature ovarian insufficiency | Diagnosis |
| Fusion Transcripts | FFPE tissue | NGS | Cancer, soft tissue and bone tumors, | Diagnosis, prognosis, treatment selection |
| GAD65 Antibody | Serum | Immunoprecipitation | Type 1 and type 2 diabetes, autoimmune (type 1, insulin-dependent) diabetes, endocrine disorders, thyroiditis, pernicious anemia, stiff-man syndrome, autoimmune encephalitis, cerebellitis, brain stem encephalitis, myelitis, organ-specific neurological disorders, myasthenia gravis, Lambert-Eaton syndrome | Diagnosis, prognosis |
| Galectin-3 (9C4) | Serum | ELISA | Benign and malignant thyroid neoplasms , anaplastic large cell lymphoma. | Diagnosis |
| Gastric Parietal Cell Antibody | Serum | ELISA | Pernicious anemia, atrophic gastritis, diabetes, gastric ulcer, thyroid disease | Diagnosis |
| Gastrin | Serum | Immunoassay | Achlorhydria, pernicious anemia, Zollinger-Ellison syndrome, gastrinoma | Diagnosis |
| GATA3 | FFPE tissue | IHC | Carcinomas, including primary bladder and breast carcinomas, and some types of mesenchymal and neuroectodermal tumors | Diagnosis |
| GCDFP-15 | FFPE tissue | IHC | Extramammary Paget disease, carcinomas of the salivary glands, sweat glands, and prostate | Diagnosis |
| GFAP | FFPE tissue | IHC | Glial tumors | Diagnosis |
| GLUT-1 | FFPE tissue | IHC | Carcinomas, fallopian tube carcinomas | Diagnosis |
| Glycophorin A | FFPE tissue | IHC | Chronic myelogenous leukemia, erythroid hypoplasia | Diagnosis |
| Glypican-3 | FFPE tissue | IHC | Hepatocellular carcinomas, hepatic adenomas | Diagnosis |
| GMS stain | Lung aspirates, others | IHC | Infectious pulmonic disease. Pneumocystis carinii and fungal organisms infections | Diagnosis |
| Gram Stain | Various | Chemical | Bacterial or fungal infection | |
| Granzyme B | FFPE tissue | IHC | Lymphomas | Diagnosis |
| Group B Streptococcus | Various | Culture/various | Group B Streptococcus infection | Diagnosis |
| H. Pylori | Breath | RI/Spectrophotometry | Helicobacter Pylori infection | Diagnosis, monitoring |
| HBME-1 | FFPE tissue | IHC | Thyroid carcinomas | Diagnosis |
| HCV (Hepatitis C Virus) | Serum | PCR | Hepatitis C virus infection | Diagnosis, monitoring |
| HCV (Hepatitis C Virus) Antibody | Serum | Immunoassay | Hepatitis C virus infection | Diagnosis, monitoring |
| Hemochromatosis Gene | Blood | PCR | Hereditary hemochromatosis (HH), | Diagnosis, prognosis |
| Her2/neu | FFPE tissue | IHC | Human breast, endometrial, ovarian, and other epithelial cancers, ductal carcinoma, solid/intracystic papillary carcinoma | Prognosis, treatment selection |
| Her2/neu Amplification | FFPE tissue | FISH | Breast carcinoma | Prognosis, treatment selection |
| HHV-6 (Human Herpesvirus 6) | Plasma | PCR | HHV-6 infection | Diagnosis |
| HHV-8 (Human Herpesvirus 8) | FFPE tissue | IHC | HHV-8 infection | Diagnosis |
| HHV-8 (Human Herpesvirus 8) | Serum, plasma | PCR | HHV-8 infection | Diagnosis |
| HIV (Human Immunodeficiency Virus) | Serum | Immunoassay | HIV infection | Diagnosis, monitoring |
| HLA-B1502 | Saliva | PCR | Epilepsy, trigeminal neuralgia, bipolar disorder | Treatment selection |
| HLA-B27 | Blood | Immunoassay | Ankylosing spondylitis, juvenile rheumatoid arthritis, Reiter syndrome | Diagnosis |
| HLA-B5701 | Blood, others | PCR | Human immunodeficiency virus (HIV) infection, renal cell carcinoma, soft tissue sarcoma | Treatment selection |
| HLA-B5801 | Blood | PCR | Gout or gouty arthritis, high uric acid levels, nephrolithiasis , cancer | Treatment selection |
| HMB-45 | FFPE tissue | IHC | Melanoma, benign nevi, tumors | Diagnosis |
| HPV (Human Papillomavirus) | Cervical specimens | PCR | HPV-16 and/or HPV-18 infection, cervical cancer | Diagnosis, prognosis |
| HSA (Hep-Par) | FFPE tissue | IHC | Hepatocellular carcinoma | Diagnosis |
| HSV (Herpes Simplex Virus) | Serum | Immunoassay | HSV infection | Diagnosis, monitoring |
| HSV-2 (Herpes Simplex Virus) | Various | PCR | Diagnosis, monitoring | |
| Human Epididymis PRO4 | Serum | Immunoassay | Epithelial ovarian cancer | Monitoring |
| IgA | Serum | Immunoassay | IgA monoclonal gammopathies and IgA-related immune deficiencies, hepatic disease, hepatitis, liver cirrhosis, connective tissue diseases, acute and chronic infections | Diagnosis, monitoring |
| IgG | Serum | Immunoassay | IgG monoclonal gammopathies and immune deficiencies, hepatic disease, hepatitis, liver cirrhosis, connective tissue diseases, acute and chronic infections, neonates with intrauterine and perinatal infections, multiple myeloma, primary systemic amyloidosis, monoclonal gammopathy of undetermined significance | Diagnosis, monitoring |
| IgM | Serum | Immunoassay | IgM monoclonal gammopathies and IgM-related immune deficiencies, hepatic disease, hepatitis, liver cirrhosis, connective tissue diseases, acute and chronic infections, neonates with intrauterine and perinatal infections, macroglobulinemia, primary systemic amyloidosis, monoclonal gammopathy of undetermined significance | Diagnosis, monitoring |
| Inhibin | Serum | Immunoassay | granulosa cell tumors, mucinous epithelial ovarian tumors | Diagnosis, monitoring |
| Intrinsic Factor Antibody | Serum | Immunoassay | Pernicious anemia | Diagnosis |
| Iron Hematoxylin | Feces | IHC | Parasitosis | Diagnosis |
| Islet Antigen 2 Antibody | Serum | Immunoprecipitation | Type 1 and type 2 diabetes mellitus | Diagnosis, prognosis |
| JAK2 Non-V617F Mutations | Blood | PCR | Polycythemia vera (PV), myeloproliferative neoplasms, thrombocytosis and myelofibrosis | Diagnosis |
| JAK2 V617F Mutation | Blood, BM | PCR | Polycythemia vera (PV), myeloproliferative neoplasms, thrombocytosis and myelofibrosis | |
| JC Virus (Human polyomavirus 2) | CSF | PCR | JC Virus infection, progressive multifocal leukoencephalopathy | Diagnosis, monitoring |
| JC Virus (Human polyomavirus 2) | CSF | ISH | JC Virus infection, progressive multifocal leukoencephalopathy | Diagnosis, monitoring |
| KAPPA | Serum | Electrophoresis | Lymphoproliferative disorders, B-cell lymphomas/leukemias. | Diagnosis |
| Ki-67 | FFPE tissue | IHC | Neoplasms, malignant lymphomas, prostatic and breast adenocarcinomas, astrocytic neoplasms, and soft tissue neoplasms | Diagnosis, prognosis |
| KRAS Mutation 7-panel | FFPE tissue | PCR | Colorectal cancer | Prognosis, treatment selection |
| Lacosamide | Serum | LC-MS/MS | Severe renal impairment, mild-to-moderate hepatic impairment, and end-stage renal disease, epilepsia | Monitoring |
| Lactoferrin | Feces | ELISA | Inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) | Diagnosis |
| Lambda | Serum | Immunoassay | Multiple myeloma (MM), light chain multiple myeloma (LCMM), Waldenstrom macroglobulinemia (WM), non-secretory myeloma (NSMM), smoldering multiple myeloma (SMM), monoclonal gammopathy of undetermined significance (MGUS), primary systemic amyloidosis (AL), and light chain deposition disease (LCDD) | Monitoring |
| Lambda | Serum | Immunoassay | Plasmacytic neoplasm | Diagnosis |
| Lamotrigine | Serum | LC-MS/MS | Bipolar I disorder, seizure disorders, Lennox-Gastaut syndrome, primary generalized tonic-clonic seizures, and partial seizures, migraine, trigeminal neuralgia, refractory depression | Monitoring |
| LD Isoenzymes | Serum | Electrophoresis | Cardiorespiratory diseases, malignancy, hemolysis, disorders of the liver, kidneys, lung, and muscle | Diagnosis |
| Leder (Chloroacetate Esterase) | Blood, FFPE | IHC | Mast cell disorders, myeloid disorders | Diagnosis |
| Lewis Y | FFPE tissue | IHC | Lung adenocarcinoma, cholangiocarcinoma, hepatocellular carcinoma, breast cancer | Diagnosis / Prognosis |
| Lipoprint | Serum plasma | Electrophoresis | Cardiovascular disease, dyslipoproteinemia, hyperlipoproteinemias, | Diagnosis, prognosis, monitoring |
| LP-PLA2 Activity | Serum | Enzymatic | Coronary heart disease | Prognosis |
| Lupus Anticoagulation | Plasma | Oher | Systemic lupus erythematosus, autoimmune disorders, collagen vascular disease | Diagnosis |
| Luxal Fast Blue | FFPE tissue | Chemical | Pathological processes in the CNS | Diagnosis |
| M. pneumoniae Antibody | Serum | Immunoassay | Mycoplasma pneumoniae infection | Diagnoisis |
| M. pneumoniae Nucliec Acid | Various | PCR | Mycoplasma pneumoniae infection | Diagnoisis |
| Mammaglobin | FFPE tissue | IHC | Human breast cancer, tumors of unknown primary site | Diagnosis |
| Mast Cell Tryptase | Serum | Immunoassay | Systemic mastocytosis, mast cell activation syndrome, Anaphylaxis, allergen challenge | Diagnosis |
| Melan-A (MART-1) | FFPE tissue | IHC | Melanoma, clear cell sarcoma, melanotic neurofibroma, melanotic schwannoma, perivascular epithelioid cell tumor | Diagnosis |
| Melanin Bleach | FFPE tissue | Chemical | Melanoma, Acral lentiginous melanoma | Diagnosis |
| Melanoma Associated Antigen | FFPE tissue | IHC | Melanoma | Diagnosis |
| Methylmalonic Acid | Serum | LC-MS/MS | Methylmalonic acidemia, cobalamin (vitamin B12) deficiency | Diagnosis, monitoring |
| Microsatellite Instability (MSI) | FFPE tissue | PCR | Hereditary nonpolyposis colorectal cancer (HNPCC)/Lynch syndrome, colorectal, endometrial cancer. gastric cancer, ovarian cancer, hepatobiliary and urinary tract carcinomas, small bowel cancer | Diagnosis, prognosis |
| MITF | FFPE tissue | IHC | Melanoma | Diagnosis |
| MLH-1 | Blood, others | Sequencing | Constitutional mismatch repair deficiency (CMMRD) / Lynch syndrome, ovarian cancer | Diagnosis, prognosis |
| MLH-1 Promoter Hypermethylation | FFPE tissue | PCR | Hereditary nonpolyposis colon cancer (HNPCC), / Lynch syndrome, | Diagnosis, prognosis |
| MOC-31 | FFPE tissue | IHC | Tumors of epithelial origin, adenocarcinomas, papillary serous carcinoma, breast, lung, prostate, and cholangiocarcinoma, among others | Diagnosis |
| MPL Codon 515 Mutation | Blood, BM | Sequencing | Myeloproliferative neoplasms (MPNs), polycythaemia vera, essential thrombocythaemia, or primary myelofibrosis | Diagnosis |
| MSH-2 | FFPE tissue | IHC | Hereditary nonpolyposis colon cancer/Lynch syndrome | Prognosis |
| MSH-6 | Blood, others | Sequencing | Hereditary nonpolyposis colon cancer/Lynch syndrome. hereditary endometrial carcinoma | Prognosis |
| MTHFR Mutation Det | Blood | Nucleic acid-based | Coronary artery disease, acute myocardial infarction, peripheral vascular artery disease, stroke, or venous thromboembolism | Diagnosis, prognosis |
| MUM-1 | FFPE tissue | IHC | Hematolymphoid neoplasms, melanomas | Diagnosis |
| Myeloperoxidase Antibody | Serum | Immunoassay | Immune-mediated vasculitis, microscopic polyangiitis (MPA) | Diagnosis, monitoring |
| Myoglobin | Serum | Immunoassay | Muscle damage | Diagnosis |
| N. gonorrhoeae | Various | PCR | Neisseria gonorrhoeae infection | Diagnosis |
| Napsin A | FFPE tissue | IHC | Carcinomas, lymphomas, primary lung adenocarcinoma | Diagnosis |
| Neurofilament | FFPE tissue | IHC | Neoplastic cells of neural origin , neuromas, gangliogliomas, neuroblastomas, medulloblastomas, pheochromocytoma, chemodectomas, and carcinoid tumors | Diagnosis |
| NGF | Various | Sequencing | Neuropathy, hereditary sensory and autonomic | Diagnosis |
| NKX3.1 | FFPE tissue | IHC | Prostate cancer, metatstatic adenocarcinoma, prostatic origin tumors | Diagnosis |
| NRAS BRAF EGFR Mutations | FFPE tissue | PCR | Lung cancer | Diagnosis, prognosis, treatment selection |
| NSE | Serum | Immunoassay | Neuron-specific enolase-secreting tumors, small cell lung carcinoma, carcinoids, islet cell tumors and neuroblastomas, comatose patients | Diagnosis, monitoring |
| N-Telopeptide | Urine | Immunoassay | Osteopenia, osteoporosis, conditions associated with increased bone turnover | Diagnosis, monitoring |
| Oncotype DX | FFPE tissue | PCR | Breast cancer | Prognosis, treatment selection |
| Osteocalcin | Serum | Immunoassay | Osteopenia, osteoporosis, Paget’s disease, disorders in which osteocalcin levels are elevated, cancer accompanied by bone metastases, primary hyperparathyroidism, renal osteodystrophy | Diagnosis, monitoring |
| p120 Catenin | FFPE tissue | IHC | Desmoid-type fibromatosis | Diagnosis |
| P16 | FFPE tissue | IHC | Human papilloma virus infection | Diagnosis |
| p40 | FFPE tissue | IHC | Carcinomas, squamous cell carcinoma, lymphomas | Diagnosis |
| P504S (AMACR) | FFPE tissue | IHC | High-grade prostatic intraepithelial neoplasia, prostate cancer | Diagnosis |
| P53 | FFPE tissue | IHC | Cancer, colon, stomach, bladder, breast, lung, and testes cancers, melanoma, lymphoma. | Diagnosis, prognosis |
| p57 | FFPE tissue | IHC | Hydatidiform Mole, Wilm’s tumor, Beckwith Wiedemann syndrome (BWS), sporadic cancers | Diagnosis |
| P63 | FFPE tissue | IHC | Squamous, urothelial, myoepithelial, tumors | Diagnosis |
| PAI-1 Genotype | Blood | PCR | Cardiovascular disease, Chronic venous insufficiency (CVI) | Prognosis |
| Pancreatic Elastase 1 | Feces | ELISA | Pancreatic Insufficiency | Diagnosis, monitoring |
| Pax5 | FFPE tissue | IHC | Lymphomas | Diagnosis |
| Pax8 | FFPE tissue | IHC | Renal cell carcinomas, ovarian carcinoma, papillary thyroid carcinomas, tumors of Mullerian origin | Diagnosis |
| PD-L1 (22C3) | FFPE tissue | IHC | Carcinomas of the urinary bladder, lung, gastric and gastroesophageal junction, thymus, colon, pancreas, ovary, breast, kidney, melanoma, glioblastoma. | Diagnosis, prognosis |
| PD-L1 (SP142) | FFPE tissue | IHC | Carcinomas of the urinary bladder, lung, thymus, colon, pancreas, ovary, breast, kidney, in melanoma, glioblastoma. | Diagnosis, prognosis |
| PD-L1: (28-8) | FFPE tissue | IHC | Non-squamous non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), urothelial carcinoma (UC), melanoma | Prognosis, treatment selection |
| PD-L1: (SP263) | FFPE tissue | IHC | Carcinomas of the urinary bladder, lung, thymus, colon, pancreas, ovary, breast, kidney, in melanoma, glioblastoma. | Diagnosis, prognosis |
| PGP 9.5 | FFPE tissue | IHC | Small fiber peripheral neuropathy | Diagnosis |
| PHH3 | FFPE tissue | IHC | Breast cancer, breast carcinomas | Diagnosis, prognosis |
| Phosphatidyl Antibody | Serum | ELISA | Antiphospholipid syndrome (APS) | Prognosis, treatment selection |
| PIN-4 (P504S, HMW Cytokeratin, p63) | FFPE tissue | IHC | Prostate cancer, prostatic adenocarcinoma, | Diagnosis |
| PLAP | FFPE tissue | IHC | Germ-cell tumors, adenocarcinomas, tumors of Mullerian derivation, pulmonary and colonic carcinomas, renal cell carcinomas. | Diagnosis |
| PML/RARA Fusion Protein | Blood | PCR | Promyelocytic leukaemia | Diagnosis, monitoring |
| PMS-2 | Blood, others | Sequencing | Lynch syndrome/hereditary nonpolyposis colorectal cancer | Diagnosis, prognosis |
| Podoplanin (D240) | FFPE tissue | IHC | Follicular dendritic cells sarcoma, mesothelioma, seminoma, epithelioid malignant mesothelioma | Diagnosis |
| PR | FFPE tissue | IHC | Breast cancer | Prognosis, treatment selection |
| PRO(P504S/KER903) | FFPE tissue | IHC | Prostate cancer | Diagnosis |
| Prothrombin G20210A Mutation | Blood | PCR | Thrombophilia | Diagnosis |
| PSA | Serum | Immunoassay | Benign prostatic hypertrophy, prostatitis, prostate cancer | Diagnosis, monitoring |
| PSAP | FFPE tissue | IHC | Prostate adenocarcinoma and urothelial carcinoma | Diagnosis |
| PTAH | FFPE tissue | Chemical | Tumours of skeletal muscles, ependymomas | Diagnosis |
| PTEN | Blood, others | Sequencing | PTEN hamartoma tumor syndrome, Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome, Proteus syndrome, Proteus-like syndrome | Diagnosis |
| Reticulin Stain | FFPE tissue | Chemical | Liver pathologies | Diagnosis |
| RF IgA IgG IgM | Serum | Immunoassay | Rheumatoid Arthritis, Henoch Schoenlein purpura, hepatitis C, Sjogren Syndrome | Diagnosis |
| Rickettsia Species Antibody | Serum | ELISA | Rickettsia species infections | Diagnosis |
| Rickettsia Species Nucleic Acid | Blood | PCR | Rickettsia species infections | Diagnosis |
| S 100 | FFPE tissue | IHC | Cartilaginous tumors, myoepithelial tumors, Schwann cells and neural tumors, Langerhans cell proliferations, benign and malignant melanocytes, clear cell sarcoma, and some carcinomas (particularly of the breast) | Diagnosis |
| S. cerevisiae | Serum | Immunoassay | Saccharomyces cerevisiae infection, baker’s yeast allegy | Diagnosis |
| Sex Hormone-Binding Globulin (SHBG) | Serum | Immunoassay | Androgen excess, polycystic ovarian syndrome, idiopathic hirsutism. disorders of puberty, anorexia nervosa, thyrotoxicosis, insulin resistance, type 2 diabetes, cardiovascular disease | Diagnosis, monitoring |
| SMA (Smooth Muscle Actin) | Serum | Immunoassay | Chronic liver disease, primary biliary cirrhosis, chronic viral hepatitis, alcoholic chronic hepatitis | Diagnosis |
| SMA (Spinal muscular atrophy) | Blood, others | PCR | Spinal muscular atrophy (SMA) | Diagnosis, prognosis, treatment selection |
| SMM (Smooth Muscle Myosin) | FFPE tissue | IHC | Benign sclerosing breast lesions, infiltrating carcinomas | Diagnosis |
| Smoothelin | FFPE tissue | IHC | Transurethral resection of urinary bladder tumor (TURBT), urothelial carcinoma, bladder carcinoma | Diagnosis |
| Solid Tumor Panel | FFPE tissue | NGS | Cancer, solid tumors | Diagnosis, prognosis, treatment selection |
| SOX10 | FFPE tissue | IHC | Malignant peripheral nerve sheath tumor, synovial sarcoma, intraneural synovial sarcoma, malignant melanoma, Schwannomas, neurofibromas. | Diagnosis |
| Stromelysin-3 | FFPE tissue | IHC | Meningiomas, invasive breast cancer, Rheumatoid Arthritis | Diagnosis, prognosis, monitoring |
| Synaptophysin | FFPE tissue | IHC | Neuronal tumors and tumors with neuroendocrine differentiation, neuroblastoma, ganglioneuroblastoma, ganglioneuroma, pheochromocytoma/paraganglioma, carcinoid/neuroendocrine carcinoma | Diagnosis |
| T Cell Gene Rearrangement | BM | PCR/GE | T cell lymphoma | Diagnosis |
| T. Pallidum Antibody | Serum | Immunoassay | Syphilis | Diagnosis |
| TdT | FFPE tissue | IHC | Leukemias, lymphomas | Diagnosis |
| Testosterone Female | Serum | LC/MS/MS | Abnormal testosterone levels,infertility, polycystic ovary syndrome (PCOS) | Diagnosis, monitoring |
| Testosterone Male | Serum | LC/MS/MS | Abnormal testosterone levels,erectile dysfunction | Diagnosis, monitoring |
| TFE3 Mutation | FFPE tissue | FISH | Renal cell carcinoma. alveolar soft-part sarcoma | Diagnosis |
| Thyroglobulin | Serum | Immunoassay, LC/MS/MS | Disordered thyroid growth, goiter, thyroiditis, thyroid cancer | Diagnosis, monitoring |
| Toluidine Blue | FFPE tissue | Chemical | Oropharyngeal carcinomas | Prognosis |
| Topiramate | Serum | LC/MS/MS | Epilepsy, seizures, Lennox-Gastaut syndrome, migraine | Monitoring |
| Total Bile Acids | Serum | Enzymatic | Liver disease, chronic hepatitis C, intrahepatic cholestasis of pregnancy | Diagnosis, monitoring |
| Tpmt Genotype | Blood, others | PCR | Acute lymphoblastic leukemia, autoimmune disorders, Crohn disease, rheumatoid arthritis, organ transplant recipients | Prognosis, treatment selection |
| Trichomonas | Urine, others | Nucleic acid-based | Trichomoniasis | Diagnosis |
| Triiodothyronine | Serum | Immunoassay | Hyperthyroidism, euthyroid patients who have an altered distribution of binding proteins | Diagnosis, monitoring |
| TSH Receptor Antibody | Serum | Immunoassay | Thyrotoxicosis, endocrine exophthalmos, pretibial myxedema, thyroid acropachy | Diagnosis, prognosis |
| TTF-1 | FFPE tissue | IHC | Carcinomas of unknown origin, squamous cell carcinoma | Diagnosis |
| Tyrosinase | FFPE tissue | IHC | Malignant melanoma | Diagnosis |
| Ureaplasma | Plasma | PCR | Ureaplasma | Diagnosis, monitoring |
| Uric Acid Stain | Urine, FFPE tissue | Chemical | Nephropathy | Diagnosis |
| Villin | FFPE tissue | IHC | Metastatic carcinomas of intestinal origin, renal cell carcinoma, bladder carcinoma, ovarian mucinous carcinomas | Diagnosis |
| Von Kossa Stain | FFPE tissue | Chemical | Calcinosis | Diagnosis |
| Von Willebrand Panel | Blood, others | NGS | Von Willebrand Disease (VWD), | Diagnosis, monitoring |
| VZV (Varicella-Zoster Virus) | FFPE tissue | IHC | Varicella-zoster virus (VZV) infection | Diagnosis |
| Warthin-Starry Stain | FFPE tissue | IHC | Spirochetes, H. pylori and microsperediate infection | Diagnosis |
| WNV (West Nile Virus) Antibody | Serum | Immunoassay | West Nile virus infection | Diagnosis |
| WNV (West Nile Virus) Nucleic acid | Plasma | PCR | West Nile virus infection | Diagnosis |
| Wt-1 | FFPE tissue | IHC | Wilms tumor | Diagnosis |
| Zika Virus Antibody | Serum | Immunoassay | Zika virus infection | Diagnosis |
| Zika Virus Nucleic acid | Serum | PCR | Zika virus infection | Diagnosis |
| Zinc Transporter 8 Antibody | Serum | Immunoassay | Type 1 diabetes mellitus (DM) | Diagnosis, prognosis |